How much does a single injection of Tislelizumab cost?

Tislelizumab (Tislelizumab) is an anti-PD-1 monoclonal antibody developed by BeiGene. It is mainly used to treat a variety of solid tumors and blood tumors, especially in the fields of non-small cell lung cancer, hepatocellular carcinoma, and esophageal cancer. It has shown good efficacy. By blocking the binding of PD-1 and its ligands, the drug relieves the suppression of the immune system by tumor cells, thereby activating the body's own immune system to attack cancer cells and achieve anti-cancer effects. As one of the few independently developed immune checkpoint inhibitors in China, tislelizumab has received widespread attention from patients and doctors since its launch.

On the price front, tislelizumab pricing has undergone significant adjustments. In the early days of the market, the market price of a single injection (specification: 100 mg) was approximately more than 10,000 yuan, which was a considerable burden for many patients. With the intervention and negotiation of the national medical insurance, tislelizumab was successfully included in the medical insurance catalog, and the price dropped significantly. After reimbursement from medical insurance, the patient's out-of-pocket payment is significantly reduced. Currently, the actual price paid in some areas ranges from a few hundred yuan to more than a thousand yuan per tube. The specific cost will vary according to the medical insurance policies and hospital pricing in different regions. This price adjustment effectively alleviates patients' financial pressure and improves drug accessibility.

Compared with domestic prices, the price of tislelizumab in overseas markets appears to be higher. Taking the United States as an example, the price of a single dose of tislelizumab is several thousand dollars, equivalent to more than 30,000 yuan. This price difference reflects differences in drug pricing strategies and health insurance systems in different countries. For domestic patients, purchasing tislelizumab through regular hospital channels can not only ensure the quality and safety of the drug, but also enjoy the price discounts brought by medical insurance and avoid the financial burden caused by high drug prices.

Overall, tislelizumab, as an immunotherapy drug innovatively developed in China, is becoming an important treatment option for cancer patients, especially lung cancer and liver cancer patients, due to its good efficacy and price advantage after being included in medical insurance. Patients should follow the doctor's guidance when using it and choose to purchase it through regular channels to ensure drug safety and therapeutic effect. At the same time, with the continuous improvement of medical insurance policies, the accessibility and cost-effectiveness of tislelizumab are expected to be further improved in the future, bringing good news to more patients.

Reference materials:https://www.drugs.com/donanemab.html